Editorial: Failure After Failure. What Next in AD Drug Development?
- PMID: 31062821
- DOI: 10.14283/jpad.2019.23
Editorial: Failure After Failure. What Next in AD Drug Development?
Conflict of interest statement
Dr. Aisen has grants from Lilly, Janssen, NIH, FNIH and the Alzheimer’s Association, and has received consulting fees from Biogen, Merck, Roche, Proclara, Eisai, Lundbeck and ImmunoBrain Checkpoint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical